20,500 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Acquired by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS acquired a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 20,500 shares of the biopharmaceutical company's stock, valued at approximately $376,000.

Several other institutional investors have also made changes to their positions in ACAD. SG Americas Securities LLC grew its position in ACADIA Pharmaceuticals by 380.3% in the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock valued at $45,576,000 after acquiring an additional 1,966,607 shares during the period. Barclays PLC grew its holdings in shares of ACADIA Pharmaceuticals by 126.2% in the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock worth $4,269,000 after purchasing an additional 154,854 shares during the last quarter. Burney Co. bought a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter worth about $6,953,000. Proficio Capital Partners LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth about $272,000. Finally, State Street Corp lifted its holdings in ACADIA Pharmaceuticals by 3.0% during the 3rd quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company's stock valued at $91,878,000 after purchasing an additional 173,084 shares during the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Mark C. Schneyer sold 3,171 shares of ACADIA Pharmaceuticals stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $17.05, for a total transaction of $54,065.55. Following the transaction, the executive vice president now owns 56,889 shares in the company, valued at $969,957.45. The trade was a 5.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the transaction, the director now owns 17,595 shares of the company's stock, valued at approximately $320,756.85. This trade represents a 21.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,169 shares of company stock valued at $242,686 in the last 90 days. 28.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on ACAD. Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a "hold" rating and a $22.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Morgan Stanley reissued an "equal weight" rating and set a $20.00 price objective on shares of ACADIA Pharmaceuticals in a report on Friday, March 7th. Needham & Company LLC restated a "buy" rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Tuesday. Finally, StockNews.com upgraded shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, March 8th. Eight research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.93.

ACADIA Pharmaceuticals Stock Performance

NASDAQ:ACAD traded down $0.85 during mid-day trading on Thursday, hitting $14.11. The company had a trading volume of 1,913,282 shares, compared to its average volume of 1,852,560. The firm has a market cap of $2.35 billion, a P/E ratio of 18.09 and a beta of 0.54. The business's fifty day moving average is $17.66 and its two-hundred day moving average is $16.97. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $13.40 and a fifty-two week high of $20.68.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.